Profound Medical Corp (PROF) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Profound Medical Corp   (NASDAQ: PROF)


Profound Medical's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Profound Medical's ROI in the second quarter of 2026?
Profound Medical Corp recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -29.12%.

Within the Healthcare sector 354 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 108 to 483.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 10.05 % 8.04 % 12.19 % 28.25 % 21.58 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 55 67 71 37 44
Return On Investment (TTM) -29.12 % 15.38 % 9.19 % 15.86 % -17.83 %
PROF's Overall Ranking # 483 # 108 # 49 # 46 # 31
Seq. Investment Change TTM 5.07 % 5.67 % 2.97 % -3.74 % 3.15 %
Seq. Net Income Change TTM - 76.91 % -40.34 % - -
Net Income (TTM) in Millions -17 8 5 8 -9

PROF Company Profile >> Back to PROF Roi Comparisons >> See Annual PROF Return On Investment



Return On Investment PROF's Ranking
Within: No.
Industry # 107
Sector # 355
Overall # 483

Return On Investment Statistics
High Average Low
76.09 %
-6.63 %
-62.79 %
(Dec 31 2023)   (Mar 31 2025)



  News about Profound Medical Corp Return on Investment ROI

Profound Medicals PRO-Talk Live! Event Showcases TULSAs Transformational Potential for Prostate Cancer Treatm...

September 16, 2024

In the rapidly evolving landscape of medical technology, events that facilitate knowledge exchange and collaborative learning are more critical than ever. Recently, Profound Medical hosted its much-anticipated PRO-Talk Live! event, a remarkable gathering that shone a spotlight on the present and future of TULSA a groundbreaking therapeutic approach for treating prostate cancer. This educational initiative aimed at physicians, stands out as a prime example of innovation-led learning within the healthcare sector. Innovative Insights from Experts The PRO-Talk Live! event brought together an esteemed roster of experts, innovators, and guest speakers, all recognized leaders in the field of medical technology and healthcare. Physicians and medical personnel were not only attendees but active participants in discussions centered on TULSA (Transurethral UltraSound Ablation), which is garnering attention as a focal point in prostate cancer treatment. The engaging discussions, interactive panels, and case study presentations highlighted how TULSA is revolutionizing patient care and changing the traditional narrative of prostate cancer therapies.

Profound Medical Corp's TULSA Procedure Receives Category 1 CPT Codes, Revolutionizing Prostate Disease Treatment and Achieving Record-Breaking ROI

July 11, 2024


TORONTO, July 11, 2024 - Profound Medical Corp (NASDAQ: PROF; TSX: PRN), a leading commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, announced a significant development today. The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed rules that establish a Category 1 CPT code for the Transurethral Ultrasound Ablation (TULSA) procedure. This landmark decision is set to come into effect on January 1, 2025.
The introduction of the Category 1 CPT codes for the TULSA procedure is a major milestone in the field of prostate disease treatment. This coding system establishes a uniform classification for medical services, enabling healthcare providers to accurately document and bill the specific procedure. The designation of a Category 1 CPT code signifies that the TULSA procedure is widely accepted and utilized within the medical community.





Financial Statements
Profound Medical's II. Quarter Investments $ 55 Millions PROF's Balance sheet
Profound Medical's II. Quarter Income $ -10 Millions Quarterly PROF's Income Statement
PROF's Income by Division See PROF's Income by Division


PROF Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 71 65 45 60 81
Y / Y Investment Growth 9.16 % 46.35 % -25.23 % -25.86 % -17.19 %
Net Income in Millions -43 -28 -28 -29 -31
Y / Y Net Income Growth - - - - -
Annual Return On Investment -59.62 % -42.53 % -63.37 % -47.96 % -38.08 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PROF's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PROF's Competitors
Subscribers only: Roi for Profound Medical's Suppliers
Subscribers only: Return On Investment for PROF's Customers

Other Ratios
PROF's Roa PROF's Inventory Turnover Ratio PROF's Growth Rates PROF's Dividend Statistics
PROF's Profitability Ratios PROF's Asset Turnover Ratio PROF's Dividend Growth
PROF's Roe PROF's Valuation Ratios PROF's Financial Strength Ratios PROF's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-08T21:43:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.